Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Birdwell CE, Fiskus W, Kadia TM, Mill CP, et al. Leukemia 2024;38:545-556.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Birdwell CE, Fiskus W, Kadia TM, Mill CP, et al. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia 2024;38:545-556.
PMID: 38086946